Mannkind Corp (MNKD)
$0.92 0.02 (2.54%)
13:33 EDT MNKD Stock Quote Delayed 20 Minutes
Previous Close $0.94
Market Cap 133.43M
PE Ratio -0.76
Volume (Avg. Vol.) 802,714
Day's Range 0.91 - 0.95
52-Week Range 0.80 - 1.91
Dividend & Yield N/A (N/A)
MNKD Stock Predictions, Articles, and Mannkind Corp News
- From InvestorPlace
- From the Web
Signs are pointing to potential big gains for penny stocks in the coming days. These 5 dollars stocks are worth owning now.
Look to low-priced biotech stocks for some big-time bargains. Here are five great ones to buy today.
MannKind scored a collaboration deal with biotechnology giant, United Therapeutics. This development partnership could pay off big.
MNKD stock collapsed after disastrously poor Q2 earnings, but the real story is that MannKind now faces a bankruptcy threat.
MannKind Corporation (MNKD) stock was sliding after the bell following the company's quarterly earnings report, which included a year-over-year Afrezza revenue growth of 142%.
With a depressed share price, sales set to double this year, and a traditionally high-growth sector, it can be tempting to view MannKind Corp. (MNKD) as a bargain. Don’t make that mistake.
Volatility has send MannKind stock's options prices through the roof. You could sell option premium here, but is MNDK worth the risk?
The Sell recommendation for Mannkind Corp is the outcome of an analytical process that is proprietary which generated conclusions that were above average in 2 areas: an economic sector rated above average in attractiveness, and a mathematical computation of risk/reward that is better than average; and produced below average results in 4 areas: an industry group rated below average in attractiveness, a ranking in the company's sector that is in the middle third, ranking in the company's industry group that is in the middle third-below average, and analytical scoring that is well below average.
Small-cap stocks with strong earnings growth and down-to-earth valuations are performing better than even the largest of blue chips.
MannKind (MNKD) options soar on Afrezza label win, Apple (AAPL) is plagued by iPhone 8 battery bloating, while Netflix (NFLX) raised prices.
MannKind (MNKD) stock was up on Tuesday despite the company reporting an earnings and revenue miss in its second quarter of 2017.
These nine companies are either on the brink of Chapter 11 or already in bankruptcy proceedings. Either way, things look grim.
Just days after announcing a breakthrough distribution pact, MNKD delivered news of smaller first-quarter losses.
MannKind (MNKD) stock is still on the rise following the announcement of its deal with One Drop and speculation of a sale.
MannKind Corporation (MNKD) shares are down as the company approved a reverse split that will reduce from 700 million to 140 million shares.
MannKind (MNKD), down 90% over the past couple of years, is still fighting an uphill, un-winnable battle. MNKD stock is nearly out of time.
Thursday’s Vital Data: Apple Inc. (AAPL), Micron Technology, Inc. (MU) and MannKind Corporation (MNKD)
Wall Street yawns at Apple (AAPL) iPhone event, Micron (MU) rides DRAM projections and MannKind (MNKD) options bet big on Mylan (MYL) EpiPen rival.
MannKind (MNKD) is in the early stages of developing an inhalable form of epinephrine, which could help it take market share from the injectable version.
From Analyst Ratings
H.C. Wainwright analyst Oren Livnat maintained a Buy rating on MannKind (MNKD – Research Report) today and set a price target of $2.50. The company’s shares closed last Monday at $1.35. According to TipRanks.com, Livnat is a 4-star analyst with an average return of 5.9% and a 48.0% success rate. Livnat covers the Healthcare sector,
From Analyst Ratings
Oppenheimer analyst Steven Lichtman maintained a Buy rating on MannKind (MNKD – Research Report) today and set a price target of $2.50. The company’s shares closed last Monday at $1.35. According to TipRanks.com, Lichtman ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.4% and a 49.0%
Navellier RatingsPowered by Portfolio Grader